<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614614</url>
  </required_header>
  <id_info>
    <org_study_id>110870</org_study_id>
    <secondary_id>110871</secondary_id>
    <nct_id>NCT00614614</nct_id>
  </id_info>
  <brief_title>Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014</brief_title>
  <official_title>Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Meningococcal Vaccine 134612 Given at 12-15 Months of Age or at 15-18 Months of Age (Co-administered With Infanrix®) in Primed Healthy Toddlers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to characterize the immunogenicity &amp; safety of a booster dose of
      GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months
      of age (co-administered with Infanrix®) in healthy toddlers primed with GSK Biological's
      Hib-meningococcal vaccine 792014. This study is single-blinded for the primary phase and
      open-label for the booster phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the titer of antibody for serogroups A, C, Y and
      W-135 and the safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given
      to toddlers who were primed with GSK Biological's Hib-meningococcal vaccine 792014. In
      addition, this study will provide immunogenicity and safety data on the co-administration of
      Infanrix with meningococcal vaccine 134612 as compared to Infanrix administered alone.

      Depending on the group the subject is assigned to, one or two blood samples will be taken out
      of the subject's arm during the study.

      The protocol posting has been updated following a protocol amendment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Antibody Titers for N. Meningitidis Serogroups A(MenA), W-135(MenW-135), C(MenC) and Y(MenY) Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 1 Group</measure>
    <time_frame>One month post vaccination at 12-15 months of age (Month 11)</time_frame>
    <description>The cut-off values assessed for hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 2 Group</measure>
    <time_frame>One month post vaccination at 15-18 months of age (Month 14)</time_frame>
    <description>The cut-off values assessed for hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 1 Group</measure>
    <time_frame>One month post vaccination at 12-15 months of age (Month 11)</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 2 Group</measure>
    <time_frame>One month post vaccination at 15-18 months of age (Month 14)</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-Diptheria (Anti-D) and Anti-Tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 2 Group and ActHIB- Infanrix Group</measure>
    <time_frame>One month post vaccination at 15-18 months of age (Month 14)</time_frame>
    <description>The cut-off value assessed for Anti-D and Anti-T were greater than or equal to (≥) 1.0 International Units per milliliter (IU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Menhibrix 2 Group</measure>
    <time_frame>One month post vaccination at 12-15 months of age (Month 11)</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Antibody Concentrations for Anti-PT (Pertusis Toxoid), Anti-FHA (Filamentous Hemagglutinin) and Anti-PRN (Pertactin) in Nimenrix 2 Group and ActHIB- Infanrix Group</measure>
    <time_frame>One month after vaccination at 15-18 months of age (Month 14)</time_frame>
    <description>Concentrations were provided as Geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Value in Menhibrix 2 Group</measure>
    <time_frame>One month post vaccination at 12-15 months of age (Month 11)</time_frame>
    <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 1 Group and Menhibrix 2 Group</measure>
    <time_frame>One month after vaccination at 12-15 months of age (Month 11)</time_frame>
    <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With hSBA-MenA and hSBA MenW-135 Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 1 Group</measure>
    <time_frame>One month after vaccination at 12-15 months of age (Month 11)</time_frame>
    <description>The cut-off values assessed for hSBA-MenA and hSBA-MenW-135 were greater than or equal to (≥) 1:4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers for hSBA-MenA and hSBA MenW-135 in Nimenrix 1 Group</measure>
    <time_frame>One month after vaccination at 12-15 months of age (Month 11)</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 2 Group</measure>
    <time_frame>Prior to vaccination at 15-18 months of age (Month 13)</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 2 Group</measure>
    <time_frame>Prior to vaccination at 15-18 months of age (Month 13)</time_frame>
    <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:4 and ≥ 1:8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-D and Anti-T Geometric Mean Antibody Concentrations</measure>
    <time_frame>One month after vaccination with Infanrix at 15-18 months of age (Month 14)</time_frame>
    <description>Concentrations were provided as Geometric Mean Concentrations(GMCs) and expressed as International Units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-D and Anti-T Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value</measure>
    <time_frame>One month after vaccination with Infanrix at 15-18 months of age (Month 14)</time_frame>
    <description>The cut-off value assessed for Anti-D and Anti-T were greater than or equal to (≥) 0.1 International Units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations Greater Than or Equal to Protocol Specified Cut-off Value</measure>
    <time_frame>One month after vaccination with Infanrix at 15-18 months of age (Month 14)</time_frame>
    <description>The cut-off values assessed were greater than or equal to (≥) 5 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations for Anti-PT, Anti-FHA and Anti-PRN in Nimenrix 1 Group and Menhibrix 2 Group</measure>
    <time_frame>One month after vaccination at 15-18 months of age (Month 14)</time_frame>
    <description>Concentrations were provided as Geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-D and Anti-T Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 1 Group and Menhibrix 2 Group</measure>
    <time_frame>One month after vaccination at 15-18 months of age (Month 14)</time_frame>
    <description>The cut-off values assessed for Anti-D and Anti-T were greater than or equal to (≥) 1.0 International Units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 2 Group</measure>
    <time_frame>One month after vaccination at 15-18 months of age (Month 14)</time_frame>
    <description>The cut-off values assessed for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY were greater than or equal to (≥) 1:4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers for hSBA-MenA and hSBA-MenW-135 in Nimenrix 2 Group</measure>
    <time_frame>One month after vaccination with Infanrix at 15-18 months of age (Month 14)</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) Following Each Dose With Nimenrix or Menhibrix Vaccine</measure>
    <time_frame>During the 8-day follow-up period (Day 0-7) after vaccination in the booster phase</time_frame>
    <description>Any was defined as any solicited local symptom reported regardless of intensity grade. Grade 3 redness and swelling was greater than (&gt;) 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs in the Booster Phase</measure>
    <time_frame>During the 8-day follow-up period (Day 0-7) after dose 4 and dose 5 vaccination</time_frame>
    <description>Any fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e ≥38.0°C, grade 3 fever was axillary temperature &gt; 40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Rash</measure>
    <time_frame>From the first booster phase visit up to six months after the last vaccination (Month 10-13 up to Month 19-22)</time_frame>
    <description>Examples of rash included hives, idiopathic thrombocytopenic purpura, petechiae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) Following Vaccination With Infanrix Vaccine</measure>
    <time_frame>During the 8-day follow-up period (Day 0-7) after vaccination in the booster phase</time_frame>
    <description>Any was defined as any solicited local symptom reported regardless of intensity grade. Grade 3 redness and swelling was &gt; 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any New Onset of Chronic Illness (NOCI) and Any Emergency Room (ER) Visits</measure>
    <time_frame>From the first booster phase visit up to six months after the last vaccination (Month 10-13 up to Month 19-22)</time_frame>
    <description>NOCIs include autoimmune disorders, asthma, type I diabetes and allergies. AEs prompting emergency room visits or physician visits are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any New Onset of Chronic Illness (NOCI) and Any Emergency Room (ER) Visits</measure>
    <time_frame>From the first primary study dose up to/excluding the first booster study dose (Month 0 up to Month 10-13)</time_frame>
    <description>NOCIs include autoimmune disorders, asthma, type I diabetes and allergies. AEs prompting emergency room visits or physician visits are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First or Single Booster Phase Vaccination</measure>
    <time_frame>During a 31-day follow-up period (Day 0-30)</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Unsolicited AEs in Nimenrix 1 Group and Menhibrix 2 Group After the Second Booster Phase Vaccination</measure>
    <time_frame>During the 31-day follow-up period (Day 0-30)</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>From the first primary study dose up to/excluding the first booster study dose (Month 0 up to Month 10-13).</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>From the first booster phase visit up to six months after the last vaccination (Month 10-13 up to Month 19-22)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1558</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>Menhibrix 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 1 Group] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Menhibrix 2 Group], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 2 Group].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ActHIB- Infanrix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)</intervention_name>
    <description>One dose in the booster phase as intramuscular injection</description>
    <arm_group_label>Menhibrix 1 Group</arm_group_label>
    <other_name>Nimenrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)</intervention_name>
    <description>Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection</description>
    <arm_group_label>Menhibrix 1 Group</arm_group_label>
    <other_name>Menhibrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix®</intervention_name>
    <description>One dose as intramuscular injection</description>
    <arm_group_label>Menhibrix 1 Group</arm_group_label>
    <arm_group_label>ActHIB- Infanrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ActHIB®</intervention_name>
    <description>Three doses in the priming phase as intramuscular injection</description>
    <arm_group_label>ActHIB- Infanrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pediarix®</intervention_name>
    <description>Three doses in the priming phase as intramuscular injection</description>
    <arm_group_label>Menhibrix 1 Group</arm_group_label>
    <arm_group_label>ActHIB- Infanrix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects for whom the investigator believes that parents/guardians can and will comply
             with the requirements of the protocol.

          -  A male or female between, and including, 6 and 12 weeks of age (+ 6 days) at the time
             of the first vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Born after 36 weeks gestation.

          -  For inclusion in the booster phase, subjects must have received all three doses in the
             primary phase.

        Exclusion Criteria:

        Exclusion criteria for enrolment (primary phase)

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             within 30 days of the first dose of study vaccine(s).

          -  Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b,
             diphtheria, tetanus, pertussis, and/or poliovirus; more than one previous dose of
             hepatitis B vaccine.

          -  History of Neisseria meningitidis, hepatitis B, Haemophilus influenzae type b,
             diphtheria, tetanus, polio or pertussis diseases.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines, or by dry natural latex rubber.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at time of enrollment.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

          -  Concurrent participation in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

        Exclusion criteria for enrolment (booster phase)

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding entry into the booster phase (Visit 4), or
             planned use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days of entry into the booster phase (Visit 4) with the exception of
             Prevnar® and Hib (see the following three criteria) (Note; licensed influenza vaccine
             is allowed throughout the study)

          -  Planned administration/administration of a fourth dose of Prevnar® within 30 days of a
             booster dose of Infanrix®

          -  Previous administration of a booster dose of Hib prior to entry to the booster phase.

          -  Previous administration of a primary dose of Hib vaccine that is not part of the study
             protocol.

          -  Previous vaccination against Neisseria meningitidis that is not part of the study
             protocol.

          -  Previous vaccination with diphtheria, tetanus and pertussis antigens outside of the
             primary phase of the study.

          -  History of Neisseria meningitidis, Hib, diphtheria, tetanus or pertussis diseases.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines, or by dry natural latex rubber.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at time of enrollment.

          -  Administration of immunoglobulins and/or any blood products within the past 3 months
             or planned administration during the study period.

          -  Concurrent participation in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benton</city>
        <state>Arkansas</state>
        <zip>72019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>208 463 3126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ark City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nies</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portage</city>
        <state>Michigan</state>
        <zip>49024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richland</city>
        <state>Michigan</state>
        <zip>49083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clyde</city>
        <state>North Carolina</state>
        <zip>28721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roy</city>
        <state>Utah</state>
        <zip>84067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>Utah</state>
        <zip>84075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <results_first_submitted>June 15, 2012</results_first_submitted>
  <results_first_submitted_qc>June 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2012</results_first_posted>
  <disposition_first_submitted>November 22, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>November 22, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 23, 2011</disposition_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal disease</keyword>
  <keyword>Toddlers</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>Meningococcal vaccines</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Human serum bactericidal assay</keyword>
  <keyword>Safety</keyword>
  <keyword>Vaccines, conjugate</keyword>
  <keyword>Booster vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110870</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110870</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110870</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110870</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110870</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110870</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110870</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1558 subjects (1276 in the Menhibrix 1 Group and 282 in ActHIB- Infanrix Group) were enrolled; however, 4 of these subjects never received vaccine. Thus, 1554 subjects (1272 in the Menhibrix 1 Group and 282 in ActHIB- Infanrix Group) were vaccinated during primary vaccination phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Menhibrix 1 Group</title>
          <description>Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 1 Group] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Menhibrix 2 Group], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 2 Group].</description>
        </group>
        <group group_id="P2">
          <title>ActHIB- Infanrix Group</title>
          <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
        </group>
        <group group_id="P3">
          <title>Nimenrix 1 Group</title>
          <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
        </group>
        <group group_id="P4">
          <title>Menhibrix 2 Group</title>
          <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
        </group>
        <group group_id="P5">
          <title>Nimenrix 2 Group</title>
          <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Vaccination Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1272"/>
                <participants group_id="P2" count="282"/>
                <participants group_id="P3" count="0">Primary vaccination phase involved subjects from MenHibrix 1 Group and ActHIB- Infanrix Group only.</participants>
                <participants group_id="P4" count="0">Primary vaccination phase involved subjects from MenHibrix 1 Group and ActHIB- Infanrix Group only.</participants>
                <participants group_id="P5" count="0">Primary vaccination phase involved subjects from MenHibrix 1 Group and ActHIB- Infanrix Group only.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1182"/>
                <participants group_id="P2" count="265"/>
                <participants group_id="P3" count="0">Primary vaccination phase involved subjects from MenHibrix 1 Group and ActHIB- Infanrix Group only.</participants>
                <participants group_id="P4" count="0">Primary vaccination phase involved subjects from MenHibrix 1 Group and ActHIB- Infanrix Group only.</participants>
                <participants group_id="P5" count="0">Primary vaccination phase involved subjects from MenHibrix 1 Group and ActHIB- Infanrix Group only.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Booster Vaccination Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Menhibrix 1 Group was re-randomized to Nimenrix 1,Menhibrix 2 and Nimenrix 2 Groups in booster phase</participants>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="432"/>
                <participants group_id="P4" count="229"/>
                <participants group_id="P5" count="409"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Menhibrix 1 Group was re-randomized to Nimenrix 1,Menhibrix 2 and Nimenrix 2 Groups in booster phase</participants>
                <participants group_id="P2" count="227"/>
                <participants group_id="P3" count="405"/>
                <participants group_id="P4" count="210"/>
                <participants group_id="P5" count="396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Menhibrix 1 Group</title>
          <description>Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during Primary Vaccination Phase.</description>
        </group>
        <group group_id="B2">
          <title>ActHIB- Infanrix Group</title>
          <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1272"/>
            <count group_id="B2" value="282"/>
            <count group_id="B3" value="1554"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="1.25"/>
                    <measurement group_id="B2" value="8.7" spread="1.25"/>
                    <measurement group_id="B3" value="8.6" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="606"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="666"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Antibody Titers for N. Meningitidis Serogroups A(MenA), W-135(MenW-135), C(MenC) and Y(MenY) Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 1 Group</title>
        <description>The cut-off values assessed for hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
        <time_frame>One month post vaccination at 12-15 months of age (Month 11)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 1 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Antibody Titers for N. Meningitidis Serogroups A(MenA), W-135(MenW-135), C(MenC) and Y(MenY) Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 1 Group</title>
          <description>The cut-off values assessed for hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 1 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA (N=0;257;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenC (N=0;286;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135 (N=0;273;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;291;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 2 Group</title>
        <description>The cut-off values assessed for hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
        <time_frame>One month post vaccination at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 2 Group</title>
          <description>The cut-off values assessed for hSBA-MenA, hSBA-MenW-135, hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA (N=0;0;0;258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenC (N=0;0;0;293)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135 (N=0;0;0;283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;0;0;303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 1 Group</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
        <time_frame>One month post vaccination at 12-15 months of age (Month 11)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 1 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 1 Group</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 1 Group.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenC (N=0;286;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3845.0" lower_limit="3310.8" upper_limit="4465.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;291;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4800.9" lower_limit="4162.0" upper_limit="5537.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 2 Group</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
        <time_frame>One month post vaccination at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 2 Group</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenC (N=0;0;0;293)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="7230.5" lower_limit="6244.1" upper_limit="8372.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;0;0;303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="7487.6" lower_limit="6604.4" upper_limit="8488.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 1 Group and Menhibrix 2 Group</title>
        <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:4</description>
        <time_frame>One month after vaccination at 12-15 months of age (Month 11)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was performed on the Nimenrix 1 and Menhibrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 1 Group and Menhibrix 2 Group</title>
          <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:4</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was performed on the Nimenrix 1 and Menhibrix 2 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenC (N=0;286;155;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="286"/>
                    <measurement group_id="O3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;291;157;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="291"/>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With hSBA-MenA and hSBA MenW-135 Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 1 Group</title>
        <description>The cut-off values assessed for hSBA-MenA and hSBA-MenW-135 were greater than or equal to (≥) 1:4</description>
        <time_frame>One month after vaccination at 12-15 months of age (Month 11)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 1 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With hSBA-MenA and hSBA MenW-135 Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 1 Group</title>
          <description>The cut-off values assessed for hSBA-MenA and hSBA-MenW-135 were greater than or equal to (≥) 1:4</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 1 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA (N=0;257;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135 (N=0;273;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers for hSBA-MenA and hSBA MenW-135 in Nimenrix 1 Group</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
        <time_frame>One month after vaccination at 12-15 months of age (Month 11)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 1 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers for hSBA-MenA and hSBA MenW-135 in Nimenrix 1 Group</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 1 Group.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA (N=0;257;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="94.8" lower_limit="84.1" upper_limit="106.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135 (N=0;273;0;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="923.9" lower_limit="776.0" upper_limit="1099.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 2 Group</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
        <time_frame>Prior to vaccination at 15-18 months of age (Month 13)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Nimenrix 2 Group</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-Men C (N=0;0;0;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="67.6" lower_limit="55.5" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;0;0;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="142.3" lower_limit="121.1" upper_limit="167.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 2 Group</title>
        <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:4 and ≥ 1:8</description>
        <time_frame>Prior to vaccination at 15-18 months of age (Month 13)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 2 Group</title>
          <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:4 and ≥ 1:8</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenC ≥ 1:4 (N=0;0;0;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenC ≥ 1:8 (N=0;0;0;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY ≥ 1:4 (N=0;0;0;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY ≥ 1:8 (N=0;0;0;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-D and Anti-T Geometric Mean Antibody Concentrations</title>
        <description>Concentrations were provided as Geometric Mean Concentrations(GMCs) and expressed as International Units per milliliter (IU/mL).</description>
        <time_frame>One month after vaccination with Infanrix at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-D and Anti-T Geometric Mean Antibody Concentrations</title>
          <description>Concentrations were provided as Geometric Mean Concentrations(GMCs) and expressed as International Units per milliliter (IU/mL).</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D (N=146;252;132;254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.259" lower_limit="7.347" upper_limit="9.285"/>
                    <measurement group_id="O2" value="7.214" lower_limit="6.592" upper_limit="7.895"/>
                    <measurement group_id="O3" value="7.360" lower_limit="6.508" upper_limit="8.323"/>
                    <measurement group_id="O4" value="7.458" lower_limit="6.820" upper_limit="8.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (N=146;252;132;253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.500" lower_limit="4.877" upper_limit="6.204"/>
                    <measurement group_id="O2" value="7.400" lower_limit="6.900" upper_limit="7.936"/>
                    <measurement group_id="O3" value="8.458" lower_limit="7.762" upper_limit="9.215"/>
                    <measurement group_id="O4" value="11.751" lower_limit="10.818" upper_limit="12.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-D and Anti-T Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value</title>
        <description>The cut-off value assessed for Anti-D and Anti-T were greater than or equal to (≥) 0.1 International Units per milliliter (IU/mL).</description>
        <time_frame>One month after vaccination with Infanrix at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-D and Anti-T Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value</title>
          <description>The cut-off value assessed for Anti-D and Anti-T were greater than or equal to (≥) 0.1 International Units per milliliter (IU/mL).</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D (N=146;252;132;254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="252"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (N=146;252;132;253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="252"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations Greater Than or Equal to Protocol Specified Cut-off Value</title>
        <description>The cut-off values assessed were greater than or equal to (≥) 5 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
        <time_frame>One month after vaccination with Infanrix at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations Greater Than or Equal to Protocol Specified Cut-off Value</title>
          <description>The cut-off values assessed were greater than or equal to (≥) 5 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (N=146;252;130;254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="252"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N=146;252;132;253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="252"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (N=146;252;132;253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="251"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations for Anti-PT, Anti-FHA and Anti-PRN in Nimenrix 1 Group and Menhibrix 2 Group</title>
        <description>Concentrations were provided as Geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
        <time_frame>One month after vaccination at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was performed on the Nimenrix 1 and Menhibrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations for Anti-PT, Anti-FHA and Anti-PRN in Nimenrix 1 Group and Menhibrix 2 Group</title>
          <description>Concentrations were provided as Geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was performed on the Nimenrix 1 and Menhibrix 2 Group.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (N=0;252;130;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="73.3" lower_limit="66.7" upper_limit="80.5"/>
                    <measurement group_id="O3" value="86.9" lower_limit="75.7" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N=0;252;132;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="321.6" lower_limit="289.9" upper_limit="356.7"/>
                    <measurement group_id="O3" value="371.7" lower_limit="321.5" upper_limit="429.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (N=0;252;132;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="203.8" lower_limit="178.7" upper_limit="232.5"/>
                    <measurement group_id="O3" value="220.2" lower_limit="183.7" upper_limit="264.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-D and Anti-T Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 1 Group and Menhibrix 2 Group</title>
        <description>The cut-off values assessed for Anti-D and Anti-T were greater than or equal to (≥) 1.0 International Units per milliliter (IU/mL).</description>
        <time_frame>One month after vaccination at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was performed on the Nimenrix 1 and Menhibrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-D and Anti-T Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 1 Group and Menhibrix 2 Group</title>
          <description>The cut-off values assessed for Anti-D and Anti-T were greater than or equal to (≥) 1.0 International Units per milliliter (IU/mL).</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was performed on the Nimenrix 1 and Menhibrix 2 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="252"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D (N=0;252;132;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (N=0;252;132;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 2 Group</title>
        <description>The cut-off values assessed for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY were greater than or equal to (≥) 1:4</description>
        <time_frame>One month after vaccination at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Values in Nimenrix 2 Group</title>
          <description>The cut-off values assessed for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY were greater than or equal to (≥) 1:4</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA (N=0;0;0;258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenC (N=0;0;0;293)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135 (N=0;0;0;283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;0;0;303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers for hSBA-MenA and hSBA-MenW-135 in Nimenrix 2 Group</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
        <time_frame>One month after vaccination with Infanrix at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers for hSBA-MenA and hSBA-MenW-135 in Nimenrix 2 Group</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Nimenrix 2 Group.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenA (N=0;0;0;258)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="92.4" lower_limit="80.6" upper_limit="105.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenW-135 (N=0;0;0;283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1582.9" lower_limit="1321.8" upper_limit="1895.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) Following Each Dose With Nimenrix or Menhibrix Vaccine</title>
        <description>Any was defined as any solicited local symptom reported regardless of intensity grade. Grade 3 redness and swelling was greater than (&gt;) 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.</description>
        <time_frame>During the 8-day follow-up period (Day 0-7) after vaccination in the booster phase</time_frame>
        <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase and had symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) Following Each Dose With Nimenrix or Menhibrix Vaccine</title>
          <description>Any was defined as any solicited local symptom reported regardless of intensity grade. Grade 3 redness and swelling was greater than (&gt;) 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.</description>
          <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase and had symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="408"/>
                <count group_id="O3" value="217"/>
                <count group_id="O4" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs in the Booster Phase</title>
        <description>Any fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e ≥38.0°C, grade 3 fever was axillary temperature &gt; 40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the 8-day follow-up period (Day 0-7) after dose 4 and dose 5 vaccination</time_frame>
        <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase and had symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs in the Booster Phase</title>
          <description>Any fever was defined as axillary temperature greater than or equal to 38.0 degree centigrade i.e ≥38.0°C, grade 3 fever was axillary temperature &gt; 40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as a general symptom that prevented normal activity. Related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase and had symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="408"/>
                <count group_id="O3" value="217"/>
                <count group_id="O4" value="384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any drowsiness, Dose 4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 drowsiness, Dose 4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related drowsiness, Dose 4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever, Dose4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 fever, Dose 4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever, Dose 4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, Dose 4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 irritability, Dose 4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related irritability, Dose4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite, Dose4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 loss of appetite, Dose4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related loss of apetite, Dose4 (N=209;408;217;384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any drowsiness, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 drowsiness, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related drowsiness, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any irritability, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="195"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 irritabiity, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related irritability, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any loss of appetite, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 loss of appetite, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related loss of appetite, Dose 5 (N=0;384;197;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="NA">Dose 5 vaccination was administered to subjects in Nimenrix 1Group and MenHibrix 2 Group only as per protocol.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Rash</title>
        <description>Examples of rash included hives, idiopathic thrombocytopenic purpura, petechiae.</description>
        <time_frame>From the first booster phase visit up to six months after the last vaccination (Month 10-13 up to Month 19-22)</time_frame>
        <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Rash</title>
          <description>Examples of rash included hives, idiopathic thrombocytopenic purpura, petechiae.</description>
          <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) Following Vaccination With Infanrix Vaccine</title>
        <description>Any was defined as any solicited local symptom reported regardless of intensity grade. Grade 3 redness and swelling was &gt; 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.</description>
        <time_frame>During the 8-day follow-up period (Day 0-7) after vaccination in the booster phase</time_frame>
        <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase and had symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) Following Vaccination With Infanrix Vaccine</title>
          <description>Any was defined as any solicited local symptom reported regardless of intensity grade. Grade 3 redness and swelling was &gt; 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.</description>
          <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase and had symptom sheet completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="385"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any New Onset of Chronic Illness (NOCI) and Any Emergency Room (ER) Visits</title>
        <description>NOCIs include autoimmune disorders, asthma, type I diabetes and allergies. AEs prompting emergency room visits or physician visits are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>From the first booster phase visit up to six months after the last vaccination (Month 10-13 up to Month 19-22)</time_frame>
        <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any New Onset of Chronic Illness (NOCI) and Any Emergency Room (ER) Visits</title>
          <description>NOCIs include autoimmune disorders, asthma, type I diabetes and allergies. AEs prompting emergency room visits or physician visits are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
          <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any NOCI(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ER visit(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any New Onset of Chronic Illness (NOCI) and Any Emergency Room (ER) Visits</title>
        <description>NOCIs include autoimmune disorders, asthma, type I diabetes and allergies. AEs prompting emergency room visits or physician visits are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>From the first primary study dose up to/excluding the first booster study dose (Month 0 up to Month 10-13)</time_frame>
        <population>The analysis was performed on Primary Total Vaccinated cohort which included all subjects who had received a study vaccine during the primary phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Menhibrix 1 Group</title>
            <description>Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during Primary Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any New Onset of Chronic Illness (NOCI) and Any Emergency Room (ER) Visits</title>
          <description>NOCIs include autoimmune disorders, asthma, type I diabetes and allergies. AEs prompting emergency room visits or physician visits are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
          <population>The analysis was performed on Primary Total Vaccinated cohort which included all subjects who had received a study vaccine during the primary phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1272"/>
                <count group_id="O2" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any NOCI(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ER visit(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First or Single Booster Phase Vaccination</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
        <time_frame>During a 31-day follow-up period (Day 0-30)</time_frame>
        <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age.during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Unsolicited Adverse Events (AEs) After the First or Single Booster Phase Vaccination</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="194"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Unsolicited AEs in Nimenrix 1 Group and Menhibrix 2 Group After the Second Booster Phase Vaccination</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
        <time_frame>During the 31-day follow-up period (Day 0-30)</time_frame>
        <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase. Analysis was performed on the Nimenrix 1 and Menhibrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age.during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age.during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Unsolicited AEs in Nimenrix 1 Group and Menhibrix 2 Group After the Second Booster Phase Vaccination</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase. Analysis was performed on the Nimenrix 1 and Menhibrix 2 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>From the first primary study dose up to/excluding the first booster study dose (Month 0 up to Month 10-13).</time_frame>
        <population>The analysis was performed on Primary Total Vaccinated cohort which included all subjects who had received a study vaccine during the primary phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Menhibrix 1 Group</title>
            <description>Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during Primary Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Primary Total Vaccinated cohort which included all subjects who had received a study vaccine during the primary phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1272"/>
                <count group_id="O2" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>From the first booster phase visit up to six months after the last vaccination (Month 10-13 up to Month 19-22)</time_frame>
        <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Booster Total Vaccinated cohort which included all subjects who had received a study vaccine during the booster phase.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="432"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-Diptheria (Anti-D) and Anti-Tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 2 Group and ActHIB- Infanrix Group</title>
        <description>The cut-off value assessed for Anti-D and Anti-T were greater than or equal to (≥) 1.0 International Units per milliliter (IU/mL).</description>
        <time_frame>One month post vaccination at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. It was performed on the Nimenrix 2 and ActHIB- Infanrix Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-Diptheria (Anti-D) and Anti-Tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to Protocol Specified Cut-off Value in Nimenrix 2 Group and ActHIB- Infanrix Group</title>
          <description>The cut-off value assessed for Anti-D and Anti-T were greater than or equal to (≥) 1.0 International Units per milliliter (IU/mL).</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. It was performed on the Nimenrix 2 and ActHIB- Infanrix Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-D (N=146;0;0;254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T (N=146;0;0;253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Menhibrix 2 Group</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
        <time_frame>One month post vaccination at 12-15 months of age (Month 11)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Menhibrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers for hSBA-MenC and hSBA-MenY in Menhibrix 2 Group</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Menhibrix 2 Group.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenC (N=0;0;155;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2676.1" lower_limit="2131.8" upper_limit="3359.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;0;157;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2227.7" lower_limit="1881.9" upper_limit="2637.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Antibody Concentrations for Anti-PT (Pertusis Toxoid), Anti-FHA (Filamentous Hemagglutinin) and Anti-PRN (Pertactin) in Nimenrix 2 Group and ActHIB- Infanrix Group</title>
        <description>Concentrations were provided as Geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
        <time_frame>One month after vaccination at 15-18 months of age (Month 14)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was performed on Nimenrix 2 and ActHIB- Infanrix Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations for Anti-PT (Pertusis Toxoid), Anti-FHA (Filamentous Hemagglutinin) and Anti-PRN (Pertactin) in Nimenrix 2 Group and ActHIB- Infanrix Group</title>
          <description>Concentrations were provided as Geometric mean concentrations (GMCs) and expressed as enzyme-linked immunosorbent assay units per milliliter (EL.U/mL)</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was performed on Nimenrix 2 and ActHIB- Infanrix Group.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (N=146;0;0;254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" lower_limit="81.7" upper_limit="101.4"/>
                    <measurement group_id="O4" value="67.7" lower_limit="62.0" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N=146;0;0;253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.9" lower_limit="369.0" upper_limit="484.6"/>
                    <measurement group_id="O4" value="353.2" lower_limit="320.8" upper_limit="388.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (N=146;0;0;253)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.1" lower_limit="274.2" upper_limit="362.1"/>
                    <measurement group_id="O4" value="189.2" lower_limit="167.2" upper_limit="214.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Value in Menhibrix 2 Group</title>
        <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
        <time_frame>One month post vaccination at 12-15 months of age (Month 11)</time_frame>
        <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Menhibrix 2 Group.</population>
        <group_list>
          <group group_id="O1">
            <title>ActHIB- Infanrix Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
          </group>
          <group group_id="O2">
            <title>Nimenrix 1 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O3">
            <title>Menhibrix 2 Group</title>
            <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
          <group group_id="O4">
            <title>Nimenrix 2 Group</title>
            <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With hSBA-MenC and hSBA-MenY Antibody Titers Greater Than or Equal to Protocol Specified Cut-off Value in Menhibrix 2 Group</title>
          <description>The cut-off values assessed for hSBA-MenC and hSBA-MenY were greater than or equal to (≥) 1:8</description>
          <population>Analysis was performed on Booster According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available against at least one study vaccine antigen component during booster phase vaccination. Analysis was only performed on the Menhibrix 2 Group.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA-MenC (N=0;0;155;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA-MenY (N=0;0;157;0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed from Month 0 up to Month 19-22. Systematically and non-systematically assessed frequent adverse events were assessed during the 8 day (Day 0-7) and 31 day (Day 0-30) period respectively after booster vaccination.</time_frame>
      <desc>Participants at risk for systematically assessed adverse events (AEs) = Booster Total Vaccinated cohort with symptom sheet completed and for non-systematically assessed other (non-serious) AEs = Booster Total Vaccinated cohort. For serious AEs, participants at risk = Primary Total Vaccinated cohort and Booster Total Vaccinated cohort respectively.</desc>
      <group_list>
        <group group_id="E1">
          <title>Menhibrix 1 Group</title>
          <description>Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during Primary Vaccination Phase.</description>
        </group>
        <group group_id="E2">
          <title>ActHIB- Infanrix Group</title>
          <description>Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age at Primary Vaccination Phase and 1 booster dose of Infanrix vaccine at 15-18 months of age at Booster Vaccination Phase.</description>
        </group>
        <group group_id="E3">
          <title>Nimenrix 1 Group</title>
          <description>Subjects received 1 dose of Nimenrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
        </group>
        <group group_id="E4">
          <title>Menhibrix 2 Group</title>
          <description>Subjects received a fourth dose of Menhibrix vaccine at 12-15 months of age and 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
        </group>
        <group group_id="E5">
          <title>Nimenrix 2 Group</title>
          <description>Subjects received 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine at 15-18 months of age during Booster Vaccination Phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cyanosis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastric volvulus</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Herpes oesophagitis</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Respiratory syncitial virus bronchiolitis</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skull fracture</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory distress</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Floppy infant</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Leukemia</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Apparent life threatening event</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <description>SAE assessed from the first primary dose up to the end of the primary ESFU period (Month 0 upto Month 10-13) for MenHibrix 1 Group and ActHIB-Infanrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Adenoidectomy</sub_title>
                <description>SAE assessed from the first booster phase visit up to 6 months after the last booster phase vaccination (Month 10-13 up to Month 19-22).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="230" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="128" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="218" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Symptom experienced during the 31-day (Days 0-30) period after the second booster phase vaccination in Nimenrix 1 Group and MenHibrix 2 Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain was experienced during the 8-day (Days0-7) post-vaccination period following each dose with Nimenrix or MenHibrix vaccine in the booster phase.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="408"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="170" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Redness was experienced during the 8-day (Days0-7) post-vaccination period following each dose with Nimenrix or MenHibrix vaccine in the booster phase.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="408"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="169" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Swelling was experienced during the 8-day (Days0-7) post-vaccination period following each dose with Nimenrix or MenHibrix vaccine in the booster phase.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="408"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="105" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain was experienced during the 8-day (Days0-7) post-vaccination period with Infanrix vaccine in the booster phase.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="385"/>
                <counts group_id="E4" subjects_affected="99" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="156" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Redness was experienced during the 8-day (Days0-7) post-vaccination period with Infanrix vaccine in the booster phase.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="385"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="171" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Swelling was experienced during the 8-day (Days0-7) post-vaccination period with Infanrix vaccine in the booster phase.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="385"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="113" subjects_at_risk="374"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <description>Symptom experienced at Dose 4 vaccination with Nimenrix [ for Nimenrix 1 Group], MenHibrix [ for MenHibrix 2 Group], Nimenrix co-administered with Infanrix [ for Nimenrix 2 Group] and Infanrix [ for ActHIB-Infanrix Group].</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="408"/>
                <counts group_id="E4" subjects_affected="97" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="161" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Symptom experienced at Dose 4 vaccination with Nimenrix [ for Nimenrix 1 Group], MenHibrix [ for MenHibrix 2 Group], Nimenrix co-administered with Infanrix [ for Nimenrix 2 Group] and Infanrix [ for ActHIB-Infanrix Group].</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="408"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Symptom experienced at Dose 4 vaccination with Nimenrix [ for Nimenrix 1 Group], MenHibrix [ for MenHibrix 2 Group], Nimenrix co-administered with Infanrix [ for Nimenrix 2 Group] and Infanrix [ for ActHIB-Infanrix Group].</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="230" subjects_at_risk="408"/>
                <counts group_id="E4" subjects_affected="128" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="218" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <description>Symptom experienced at Dose 4 vaccination with Nimenrix [ for Nimenrix 1 Group], MenHibrix [ for MenHibrix 2 Group], Nimenrix co-administered with Infanrix [ for Nimenrix 2 Group] and Infanrix [ for ActHIB-Infanrix Group].</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="209"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="408"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="138" subjects_at_risk="384"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <description>Symptom experienced at Dose 5 vaccination with Infanrix vaccine for Nimenrix 1 Group and MenHibrix 2 Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Symptom experienced at Dose 5 vaccination with Infanrix vaccine for Nimenrix 1 Group and MenHibrix 2 Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Symptom experienced at Dose 5 vaccination with Infanrix vaccine for Nimenrix 1 Group and MenHibrix 2 Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="195" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="103" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <description>Symptom experienced at Dose 5 vaccination with Infanrix vaccine for Nimenrix 1 Group and MenHibrix 2 Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="197"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Symptom experienced during the 31-day (Days 0-30) period after the first or single booster phase vaccination in all groups corresponding to Booster phase of study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Symptom experienced during the 31-day (Days 0-30) period after the first or single booster phase vaccination in all groups corresponding to Booster phase of study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Symptom experienced during the 31-day (Days 0-30) period after the second booster phase vaccination in Nimenrix 1 Group and MenHibrix 2 Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Symptom experienced during the 31-day (Days 0-30) period after the second booster phase vaccination in Nimenrix 1 Group and MenHibrix 2 Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="432"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

